As Bigfoot awaits FDA clearance for its Bigfoot Unity System, the diabetes treatment company’s business model calls for packing the System as part of a one-stop-shop monthly subscription model.

Glooko will use the proceeds to expand into new geographies and take advantage of rising reimbursement for digital health, expand solutions for co-morbid conditions, and explore tuck-in acquisitions.

Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds. 

With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.